Fulcrum Therapeutics (FULC)

• Market cap: $508M
• 1 day: 0.32%
• 5 days: 3.3%
• 1 month: 2.07%
• 3 months: 36.09%
• 6 months: 143.9%
• Year to date: 94.01%
• 1 year: 189.81%
• 5 years: -4.77%
• 10 years: -30.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45